<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=348185225613720&amp;ev=PageView&amp;noscript=1">
Skip to content

An Innovative Antibody Discovery Workflow Leveraging Machine Learning to Prioritize Leads

 
On-Demand Webinar
 
Omics-Tech-Spotlight_Webinar4_Laptop2

About the workshop

Antibody generation and validation can be time-consuming, taking up to 6-12 months using traditional screening and production methods. Even after a thorough antibody campaign, candidates often result in late-stage failure. In this webinar, explore how advancements to antibody screening methods can help you discover and develop your mAb therapies more quickly and efficiently, allowing you to generate a diverse list of antibody candidates for recombinant production with promising biophysical profiles for commercialization.

 

What you'll learn about

  • The challenges of traditional antibody screening and production workflows
  • Development of alternative technologies to increase speed, cost-effectiveness, antibody diversity, and more
  • How high-throughput screening and computational approaches can generate 5-50x more antibody leads

 

Unable to attend live? Register today and we’ll send the recording to watch at your convenience.

About the presenter

TechSeries_CrystalRichardson_500px

Crystal Richardson, Ph.D.

Senior Business Partnership Manager​, Azenta Life Sciences

Dr. Crystal Richardson earned her Ph.D. from the University of Virginia with a degree in biomedical sciences. She has over six years of experience in molecular biology with a focus on clinical immunology. At Azenta, Dr. Richardson supports business operations and is our subject matter expert for adeno-associated virus (AAV) and recombinant antibody production.

Watch now

10014-D_Omics-Tech-Spotlight_EM-Graphic

Explore upcoming and on-demand omics webinars as part of our Omics Technology Spotlight Webinar Series